Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new sham-controlled trial challenges the perceived benefits of catheter ablation for atrial fibrillation. The PVI-SHAM-AF trial found that while ablation reduced AF recurrence at 6 months, it did not meaningfully improve patients' quality of life compared to a sham procedure. The findings suggest the procedure's impact on well-being may have been overestimated in prior research.
A new randomized, double-blind trial is raising important questions in the cardiology world. The PVI-SHAM-AF trial, presented at the European Society of Cardiology Congress and simultaneously published in The Lancet, found that catheter ablation did not significantly improve quality of life at 6 months compared to a sham procedure in patients with symptomatic atrial fibrillation (AF). The trial enrolled 262 patients across nine sites in Germany and Poland.
The results stand in contrast to the 2024 SHAM-PVI trial, which found that ablation did improve quality of life over sham. Researchers note that the robust response seen in the sham group — which involved conscious sedation and groin punctures but no actual ablation — may reflect the meaningful effect of attentive human care on patient-reported outcomes.
By the Numbers:
Why it matters: These findings push clinicians to rethink when ablation is truly warranted. If quality of life is the primary goal, the evidence is now less clear-cut — and the role of supportive care in patient outcomes deserves greater attention.
